Cyfra211在宫颈癌新辅助化疗疗效评价中作用.docVIP

Cyfra211在宫颈癌新辅助化疗疗效评价中作用 　　[摘要] 目的 探讨细胞角蛋白19片段抗原21-1(Cyfra21-1)检测在宫颈癌新辅助化疗疗效评价中的作用。方法 应用电化学发光法检测53例健康人、60例CIN1-3级患者、56例宫颈癌患者血清Cyfra21-1和对需行新辅助化疗的44例宫颈癌患者化疗前后的血清Cyfra21-1进行比较。结果 宫颈癌患者的血清Cyfra21-1与健康人、CIN1-3患者血清Cyfra21-1值的差异有统计学意义(P0.05);化疗前后血清Cyfra21-1值有统计学意义(P0.05);化疗后肿块缩小的程度与血清Cyfra21-1下降程度有统计学意义,血清Cyfra21-1下降50%,表明肿块缩小至少25%。结论 血清Cyfra2-1的检测对评价宫颈癌患者新辅助化疗效果具有肯定的临床意义。 　　[关键词] Cyfra21-1; 宫颈癌; 新辅助化疗(NACT) 　　[中图分类号] R737.33 [文献标识码] A [文章编号] 1673-9701(2010)15-05-02 　　 　　Role of Cyfra21-1 Detection in Evaluation of Cervical Cancer New Adjuvant Chemotherapy 　　ZHONG Qian LIU Wanmin ZHANG Weijian LIAN Xiaoqin WANG Haiqing LIU Fang 　　Guangdong Province Jiangmen City Central Hospital,Jiangmen 529000,China 　　 　　[Abstract] ObjectiveTo investigate the role of the cytokeratin 19 fragment antigen 21-1(Cyfra21-1) level detection in the evaluation of cervical cancer new adjuvant chemotherapy. MethodsSerum Cyfra21-1 level was detected in 53 healthy adults and 60 cases of CIN1-3 and 56 cases of cervical cancer by chemiluminescence immunoassay and the serum Cyfra21-1 level in 44 cases of cervical cancer by neo-adjuvant chemotherapy was compared before and after chemotherapy. ResultsThere were significant differences between serum Cyfra21-1 level in cervical cancer and serum Cyfra21-1 levels in healthy people and CIN1-3 cases(P0.05). There was a significant difference in serum Cyfra21-1 level before chemotherapy compared with post-chemotherapy serum Cyfra21-1 level(P0.05). There was a significant difference between post-chemotherapy tumor size and serum Cyfra21-1 level. When serum Cyfra21-1 level decreased by 50%,the tumor size shrunk by at least 25%. ConclusionThe serum Cyfra2-1 level detection is of great value in evaluating cervical cancer neoadjuvant chemotherapy. 　　[Key words]Cyfra21-1; Cervical cancer; New adjuvant chemotherapy(NACT) 　　 　　宫颈癌是妇科常见肿瘤,且有上升趋势。但在临床能监测宫颈癌治疗效果的肿瘤标志物较少,细胞角蛋白19片段抗原21-1(cytokeratin 19 fragment antigen 21-1,Cyfra21-1)在肺癌、鼻咽癌、食管癌等其他上皮来源的恶性肿瘤都有不同程